AV Dosing and AE Management in Patients With Untreated CLL Part 3: Management of AEs With AV

This Case-Based Exchange marks the final installment in our 3-part series, featuring discussions on a patient case involving chronic lymphocytic leukemia (CLL).

In the last video of this series, Mary Elizabeth DiLorenzo, MSN, RN, NP-BC, and Jamila Brutus, MSN, BSN, ANP-BC, RN, focus on adverse events (AEs) with fixed-duration acalabrutinib + venetoclax (AV). Together, they discuss best practices from their institutions for identifying and managing AEs to balance treatment efficacy with the patient’s quality of life.

Download Transcript